Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is twofold: 1). to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2). to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

Deadlines:

  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

PA-18-902 Expiration Date September 8, 2021

Eligibility

Faculty

Category

Engineering and Physical Sciences
Environmental & Life Sciences
Interdisciplinary
Medical
Medical - Clinical Science
Medical - Translational

External Deadline

October 5, 2019